menu
    • menu

    Company profile for ALX Oncology

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-b...
    ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ALX OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    866 Malcolm Road, Suite 100 Burlingame, CA 94010
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alxoncology.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/alexo-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AACR Annual meeting

    AACR Annual meeting

    Not Confirmed

    envelop Contact Supplier

    AACR Annual meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ALX Oncology Reports Nasdaq Listing Rule-Compliant Grant
    ALX Oncology Reports Nasdaq Listing Rule-Compliant Grant

    17 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/17/3276481/0/en/ALX-Oncology-Reports-Inducement-Grant-as-permitted-by-the-Nasdaq-Listing-Rules.html

    GLOBENEWSWIRE
    17 Apr 2026
    Share Share
    ALX Oncology Names Jeff Knight Chief Development and Operations
    ALX Oncology Names Jeff Knight Chief Development and Operations

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272501/0/en/ALX-Oncology-Appoints-Jeff-Knight-as-Chief-Development-and-Operating-Officer.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    ALX Oncology Reports 2025 Financials, Corporate Update
    ALX Oncology Reports 2025 Financials, Corporate Update

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246481/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    ALX Oncology to Report Q4, FY 2025 Financial Results Feb. 27
    ALX Oncology to Report Q4, FY 2025 Financial Results Feb. 27

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241104/0/en/ALX-Oncology-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-27-2026.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    ALX Oncology To Present At Investor Conferences In Q1 2026
    ALX Oncology To Present At Investor Conferences In Q1 2026

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241126/0/en/ALX-Oncology-to-Present-at-Upcoming-Investor-Conferences-in-Q1-2026.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    ALX Oncology Announces Pricing Of Underwritten Offering
    ALX Oncology Announces Pricing Of Underwritten Offering

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229530/0/en/ALX-Oncology-Announces-Pricing-of-Underwritten-Offering.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search